Medicines lifecycle is critical to fostering patient access to innovative therapeutic solutions, and delivering better health outcomes for patients.

Latest resource

Main deliverables

Main deliverable

Sort by
Sort by

Report of the Internal consultation on patient engagement sustainability

In June 2018, an internal consultation was organized by EURORDIS to explore with its members the different dimension of the sustainability of the patient engagement in medicines R&D.

18 March, 2019

Report for consultation with young persons: KidsBarcelona FSJD

Online survey may not be the most adequate method for understanding the views of some patient groups. Some patients may have some specific needs that have to be considered and addressed.

18 March, 2019

Consultation on Patient Engagement on development of medicines in dementia

PARADIGM WP1 aims to gain a better understanding of the needs, expectations and aspirations of the different stakeholders involved in patient engagement in the development of medicines and research.

18 March, 2019

D1.1 Survey analysis report on stakeholder-specific preferences, needs and expectations

To understand the needs, expectations and preferences from the perspective of different stakeholders, Work Package 1 (WP1) co-created with other WPs an online survey. The survey received 372 English language responses and 169 responses from 13 other European languages during the June and July in 2018. In addition to the survey, between June and October 2018, four different face-to-face consultations were carried out to involve the following vulnerable/ underrepresented and specific stakeholder groups : people with dementia, children and young 3 persons and people with rare diseases, as well as Health Technology Assessment (HTA) bodies.

18 March, 2019

PARADIGM at a glance

Meet the PARADIGM Consortium and get to know some interesting facts about them. PARADIGM’s mission is to provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players.

31 January, 2019

PARADIGM Newsletter – 6 months of impact in patient engagement

Why yet another newsletter? Well, it's about creating a community as much as it is about communicating. We want to continue to build the base of participants in co-creating solutions to make patient engagement a greater reality.

17 October, 2018

PARADIGM One-pager 2018

PARADIGM’s objective is to develop much needed patient engagement processes and tools for three key decision-making points of the medicines development lifecycle: Research priority setting, Design of clinical trials and Early dialogue with regulators and HTA bodies.

2 August, 2018

Evolution of the Patient Engagement Ecosystem

Medicines lifecycle is critical to fostering patient access to innovative therapeutic solutions, and delivering better health outcomes for patients.

21 June, 2018

PARADIGM – 1st Open Patient Engagement Forum 2018

Patients Active in Research and Dialogues for an Improved Generation of Medicines (PARADIGM) had its first Open Patient Engagement Forum on the 10th of April in Brussels co-organised by PARADIGM, PFMD and EUPATI. The forum had four workshops focusing on prioritisation of the PARADIGM survey topics, building the PARADIGM story, assessing the value of patient engagement and utilising the survey to identify key stakeholders and most suited methodologies for the project. Follow the link for a short report on the events of the day:

20 June, 2018